News and Announcements
EDITORIAL
From epidemiology to precision prevention: Why the latest breast cancer roadmap deserves your attention
Show Less
1
Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), RWTH University Hospital Aachen, Aachen D-52074,
Germany
JBM, e99010081 https://doi.org/10.14440/jbm.0276
Submitted: 26 August 2025 | Accepted: 9 September 2025 | Published: 7 October 2025
© 2025 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Conflict of interest
Ralf Weiskirchen is an Editorial Board Member of this journal. The author declared that he has no known competing financial interests or personal relationships that could have influenced the work reported in this paper.
References
[1]
- Anton SC, Lazan A, Grigore M, et al. Current trends in breast cancer genetics, risk factors, and screening strategies. J Biol Methods. 2025;12(2):e99010054. doi: 10.14440/jbm.2025.0079
- Hao J, Gong Y, Zhang X, et al. Global burden of breast cancer and application of patient-reported outcomes in clinical trials: A systematic analysis based on the global burden of disease study 2021 and WHO international clinical trial register database. Front Oncol. 2025;15:1557080. doi: 10.3389/fonc.2025.1557080
- Xiong X, Zheng LW, Ding Y, et al. Breast cancer: Pathogenesis and treatments. Signal Transduct Target Ther. 2025;10(1):49. doi: 10.1038/s41392-024-02108-4
- Batran RA, Tahoun S, Helmy L, et al. Breast cancer in the Middle East and North Africa: Economic burden, market trends, and care challenges. JCO Oncol Pract. 2025:OP2500354. doi: 10.1200/op-25-00354
- Toss A, Ponzoni O, Riccò B, et al. Management of PALB2- associated breast cancer: A literature review and case report. Clin Case Rep. 2023;11(8):e7747. doi: 10.1002/ccr3.7747
- Boonen RACM, Vreeswijk MPG, Van Attikum H. CHEK2 variants: Linking functional impact to cancer risk. Trends Cancer. 2022;8(9):759-770. doi: 10.1016/j.trecan.2022.04.009
- Yang X, Song H, Leslie G, et al. Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D. J Natl Cancer Inst. 2020;112(12):1242-1250. doi: 10.1093/jnci/djaa030